183428-91-3

Usage

Chemical Properties

Yellow solid

InChI:InChI=1/C8H6ClN3/c9-6-1-2-7-5(3-6)4-11-8(10)12-7/h1-4H,(H2,10,11,12)

Upstream product

• 544-92-3 copper(I) cyanide 
• 3430-21-5 5-bromo-3-methyl-pyridin-2-ylamine 
• 557-21-1 zinc(II) cyanide 

Downstream Products

• 731822-77-8 2-(3-bromophenyl)-8-methylimidazo[1,2-a]pyridine-6-carbonitrile 
• 167626-78-0 6-amino-5-methyl-pyridine-3-carboxylic acid 
• 731822-81-4 N-hydroxy-2-[4'-(N-hydroxyamidino)biphenyl-3-yl]-8-methylimidazo[1,2-a]pyridine-6-carboxamidine 
• 731822-44-9 N-hydroxy-2-{5-[4-(N-hydroxyamidino)phenyl]furan-2-yl}-8-methylimidazo[1,2-a]pyridine-6-carboxamidine 
• 731822-79-0 2-(4'-cyanobiphenyl-3-yl)-8-methylimidazo[1,2-a]pyridine-6-carbonitrile 
• 731822-42-7 2-[5-(4-cyanophenyl)furan-2-yl]-8-methylimidazo[1,2-a]pyridine-6-carbonitrile 

Relevant academic research and scientific papers

AMIDE COMPOUNDS, COMPOSITIONS AND APPLICATIONS THEREOF

The present disclosure relates to substituted amide compounds that are inhibitors of Fatty Acid Amide Hydrolase (FAAH), their stereoisomers, tautomers, prodrugs, polymorphs, solvates, pharmaceutically acceptable salts, and pharmaceutical compositions cont

Synthesis and pharmacological evaluation of 6-aminonicotinic acid analogues as novel GABAA receptor agonists

A series of 6-aminonicotinic acid analogues have been synthesized and pharmacologically characterized at native and selected recombinant GABA A receptors. 6-Aminonicotinic acid (3) as well as 2- and 4-alkylated analogues (9-11, 14-16) display low to mid-micromolar GABAAR binding affinities to native GABAA receptors (Ki 1.1-24 μM). The tetrahydropyridine analogue of 3 (22) shows low-nanomolar affinity (K i 0.044 μM) and equipotency as an agonist to GABA itself as well as the standard GABAA agonist isoguvacine. Cavities surrounding the core of the GABA binding pocket were predicted by molecular interaction field calculations and docking studies in a α1β 2γ2 GABAA receptor homology model, and were confirmed by affinities of substituted analogues of 3. The tight steric requirements observed for the remarkably few GABAAR agonists reported to date is challenged by our findings. New openings for agonist design are proposed which potentially could facilitate the exploration of different pharmacological profiles within the GABAAR area.

AMIDE COMPOUNDS, COMPOSITIONS AND APPLICATIONS THEREOF

The present disclosure relates to substituted amide compounds that are inhibitors of Fatty Acid Amide Hydrolase (FAAH), their stereoisomers, tautomers, prodrugs, polymorphs, solvates, pharmaceutically acceptable salts, and pharmaceutical compositions cont

Novel dicationic imidazo[1,2-a]pyridines and 5,6,7,8,-tetrahydro-imidazo[1,2,-a]pyridines as antiprotozoal agents

A method for treating a microbial infection, including an infection from a protozoan pathogen, such as Trypanosoma brucei rhodesiense and Plasmodium falciparum, in a subject in need thereof by administering to the subject an effective amount of a dication

Novel dicationic imidazo[1,2-a]pyridines and 5,6,7,8-tetrahydro-imidazo[1, 2-a]pyridines as antiprotozoal agents

2-[5-(4-Amidinophenyl)-furan-2-yl]-5,6,7,8-tetrahydro-imidazo [1,2-a]pyridine-6-carboxamidine acetate salt (7) was synthesized from 2-[5-(4-cyanophenyl)-furan-2-yl]-imidazo[1,2-a]pyridine-6-carbonitrile (4a), through the bis-O-acetoxyamidoxime followed by

PYRIDINONE THROMBIN INHIBITORS

Compounds of the invention are useful in inhibiting thrombin and associated thrombotic occlusions and have the following structure: STR1 for example: STR2